Managing childhood allergies and immunodeficiencies during respiratory virus epidemics – The 2020 COVID-19 pandemic: A statement from the...
Brough H. A., Kalayci O., Sediva A., Untersmayr E., Munblit D. B., Rodriguez d. R. P., Vazquez-Ortiz M., Arasi S., Alvaro-Lozano M., Tsabouri S., Galli E., Beken B., Eigenmann P. A.
Pediatric Allergy and Immunology
Vol.31, Issue5, P. 442-448
Опубликовано: 2020
Тип ресурса: Обзор
Аннотация:
While the world is facing an unprecedented pandemic with COVID-19, patients with chronic diseases need special attention and if warranted adaptation of their regular treatment plan. In children, allergy and asthma are among the most prevalent non-communicable chronic diseases, and healthcare providers taking care of these patients need guidance. At the current stage of knowledge, children have less severe symptoms of COVID-19, and severe asthma and immunodeficiency are classified as risk factors. In addition, there is no evidence that currently available asthma and allergy treatments, including antihistamines, corticosteroids, and bronchodilators, increase the risk of severe disease from COVID-19. Most countries affected by COVID-19 have opted for nationwide confinement, which means that communication with the primary clinician is often performed by telemedicine. Optimal disease control of allergic, asthmatic, and immunodeficient children should be sought according to usual treatment g
Ключевые слова:
allergy; asthma; biologics; children; coronavirus; corticosteroids; COVID-19; immunodeficiency; SARS-CoV-2; treatment
antiallergic agent; antiasthmatic agent; allergic disease; allergy; asthma; child; child health care; coronavirus disease 2019; disease predisposition; disease severity; high risk population; human; hygiene; immune deficiency; pandemic; practice guideline; priority journal; Review; risk factor; telemedicine; virus infection
Язык текста: Английский
ISSN: 1399-3038
Brough H. A.
Kalayci O.
Sediva A.
Untersmayr E.
Munblit D. B. Daniil Borisovich 1980-
Rodriguez d. R. P. del Rio P.
Vazquez-Ortiz M.
Arasi S.
Alvaro-Lozano M.
Tsabouri S.
Galli E.
Beken B.
Eigenmann P. A.
Броугх Х. А.
Калайcи О.
Седива А.
Унтерсмайр Е.
Мунблит Д. Б. Даниил Борисович 1980-
Родригуез д. Р. П. дел Рио П.
Вазqуез-Ортиз М.
Араси С.
Алваро-Лозано М.
Цабоури С.
Галли Е.
Бекен Б.
Еигенманн П. А.
Managing childhood allergies and immunodeficiencies during respiratory virus epidemics – The 2020 COVID-19 pandemic: A statement from the EAACI-section on pediatrics
Managing childhood allergies and immunodeficiencies during respiratory virus epidemics – The 2020 COVID-19 pandemic: A statement from the...
Текст визуальный непосредственный
Pediatric Allergy and Immunology
Munksgaard International Publishers
Vol.31, Issue5 P. 442-448
2020
Обзор
allergy asthma biologics children coronavirus corticosteroids COVID-19 immunodeficiency SARS-CoV-2 treatment
antiallergic agent antiasthmatic agent allergic disease allergy asthma child child health care coronavirus disease 2019 disease predisposition disease severity high risk population human hygiene immune deficiency pandemic practice guideline priority journal Review risk factor telemedicine virus infection
While the world is facing an unprecedented pandemic with COVID-19, patients with chronic diseases need special attention and if warranted adaptation of their regular treatment plan. In children, allergy and asthma are among the most prevalent non-communicable chronic diseases, and healthcare providers taking care of these patients need guidance. At the current stage of knowledge, children have less severe symptoms of COVID-19, and severe asthma and immunodeficiency are classified as risk factors. In addition, there is no evidence that currently available asthma and allergy treatments, including antihistamines, corticosteroids, and bronchodilators, increase the risk of severe disease from COVID-19. Most countries affected by COVID-19 have opted for nationwide confinement, which means that communication with the primary clinician is often performed by telemedicine. Optimal disease control of allergic, asthmatic, and immunodeficient children should be sought according to usual treatment g